PDF(Pubmed)
Abstract：
Multi-cancer early detection (MCED) tests are blood-based tests designed to screen for signals of multiple cancers. There is growing interest and investment in examining the potential benefits and applications of MCED tests. If MCED tests are shown to have clinical utility, it is important to ensure that all people-regardless of their demographic or socioeconomic background-equitably benefit from these tests. Unfortunately, with health care innovation, such considerations are often ignored until after inequities emerge. We urge for-profit companies, scientists, clinicians, payers, and government agencies to prioritize equity now-when MCEDs are still being developed and researched. In an effort to avoid creating and exacerbating cancer inequities, we propose 9 equity considerations for MCEDs.
摘要：
多癌早期检测（MCED）测试是基于血液的测试，旨在筛选多种癌症的信号。在检查MCED测试的潜在益处和应用方面，人们越来越感兴趣和投资。如果MCED测试显示具有临床实用性，重要的是要确保所有人，无论其人口或社会经济背景如何，都能从这些测试中公平受益。不幸的是,通过医疗保健创新，在不平等出现之前，这种考虑往往被忽视。我们敦促营利性公司，科学家,临床医生,付款人,和政府机构现在优先考虑公平-当MCED仍在开发和研究时。为了避免造成和加剧癌症不平等，我们为MCED提出了9个股权考虑因素。
